{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:08:54Z","timestamp":1774314534818,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"DOI":"10.7759\/cureus.98525","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:42:27Z","timestamp":1764949347000},"source":"Crossref","is-referenced-by-count":1,"title":["Previously Incarcerated Veteran: A Case of Drug-Induced Parkinsonism"],"prefix":"10.7759","author":[{"given":"Brian R","family":"Bailey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The","volume":"373","author":"Leucht S","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The. Lancet. 2009, 373:31-41. 10.1016\/S0140-6736(08)61764-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn M","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al.. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019, 394:939-51. 10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis S","year":"2023","unstructured":"Siafis S, Wu H, Wang D, et al.. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023, 28:3267-77. 10.1038\/s41380-023-02203-y","journal-title":"Mol Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2008.073312","article-title":"Drug induced parkinsonism: a common cause of parkinsonism in older people","volume":"85","author":"Thanvi B","year":"2009","unstructured":"Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009, 85:322-6. 10.1136\/pgmj.2008.073312","journal-title":"Postgrad Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S360268","article-title":"Updated perspectives on the management of drug-induced parkinsonism (DIP): insights from the clinic","volume":"18","author":"Feldman M","year":"2022","unstructured":"Feldman M, Marmol S, Margolesky J. Updated perspectives on the management of drug-induced parkinsonism (DIP): insights from the clinic. Ther Clin Risk Manag. 2022, 18:1129-42. 10.2147\/TCRM.S360268","journal-title":"Ther Clin Risk Manag"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13384","article-title":"Polypharmacy in schizophrenia","volume":"126","author":"Baandrup L","year":"2020","unstructured":"Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020, 126:183-92. 10.1111\/bcpt.13384","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12837","article-title":"Case of risperidone-induced tardive parkinsonism","volume":"73","author":"Bolu A","year":"2019","unstructured":"Bolu A, Garip B, \u00d6znur T, Uzun \u00d6. Case of risperidone-induced tardive parkinsonism. Psychiatry Clin Neurosci. 2019, 73:285-6. 10.1111\/pcn.12837","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.456","article-title":"Impact of FDA black box advisory on antipsychotic medication use","volume":"170","author":"Dorsey ER","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010, 170:96-103. 10.1001\/archinternmed.2009.456","journal-title":"Arch Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem BR","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021, 397:2284-303. 10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris HR","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. Lancet. 2024, 403:293-304. 10.1016\/S0140-6736(23)01478-2","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176819","article-title":"Experimental models of Parkinson's disease: challenges and opportunities","volume":"980","author":"Lal R","year":"2024","unstructured":"Lal R, Singh A, Watts S, Chopra K. Experimental models of Parkinson's disease: challenges and opportunities. Eur J Pharmacol. 2024, 980:176819. 10.1016\/j.ejphar.2024.176819","journal-title":"Eur J Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15222","article-title":"Haloperidol-induced catalepsy as an animal model for parkinsonism: a systematic review of experimental studies","volume":"53","author":"Waku I","year":"2021","unstructured":"Waku I, Magalh\u00e3es MS, Alves CO, de Oliveira AR. Haloperidol-induced catalepsy as an animal model for parkinsonism: a systematic review of experimental studies. Eur J Neurosci. 2021, 53:3743-67. 10.1111\/ejn.15222","journal-title":"Eur J Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00579.2018","article-title":"Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug-induced Parkinsonism","volume":"120","author":"C\u00e1ceres-Ch\u00e1vez VA","year":"2018","unstructured":"C\u00e1ceres-Ch\u00e1vez VA, Hern\u00e1ndez-Mart\u00ednez R, P\u00e9rez-Ortega J, Herrera-Valdez MA, Aceves JJ, Galarraga E, Bargas J. Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug-induced Parkinsonism. J Neurophysiol. 2018, 120:2922-38. 10.1152\/jn.00579.2018","journal-title":"J Neurophysiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.06.014","article-title":"Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons","volume":"91","author":"Kharkwal G","year":"2016","unstructured":"Kharkwal G, Brami-Cherrier K, Lizardi-Ortiz JE, et al.. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016, 91:67-78. 10.1016\/j.neuron.2016.06.014","journal-title":"Neuron"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01078-z","article-title":"An evidence-based update on anticholinergic use for drug-induced movement disorders","volume":"38","author":"Vanegas-Arroyave N","year":"2024","unstructured":"Vanegas-Arroyave N, Caroff SN, Citrome L, et al.. An evidence-based update on anticholinergic use for drug-induced movement disorders. CNS Drugs. 2024, 38:239-54. 10.1007\/s40263-024-01078-z","journal-title":"CNS Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers GA","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM, et al.. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020, 177:868-72. 10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758562","article-title":"Accuracy of ophthalmology clinic follow-up in the incarcerated patient population","volume":"14","author":"Abou-Jaoude MM","year":"2022","unstructured":"Abou-Jaoude MM, Crawford J, Kryscio RJ, Moore DB. Accuracy of ophthalmology clinic follow-up in the incarcerated patient population. J Acad Ophthalmol (2017). 2022, 14:e258-62. 10.1055\/s-0042-1758562","journal-title":"J Acad Ophthalmol (2017)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01997-z","article-title":"Patient journey of veterans with schizophrenia: an analysis of treatment patterns, healthcare resource utilization and costs","volume":"39","author":"Patel C","year":"2022","unstructured":"Patel C, Huang A, Wang L, Paliwal Y, Joshi K. Patient journey of veterans with schizophrenia: an analysis of treatment patterns, healthcare resource utilization and costs. Adv Ther. 2022, 39:1199-214. 10.1007\/s12325-021-01997-z","journal-title":"Adv Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.011","article-title":"Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations","volume":"20","author":"Brigo F","year":"2014","unstructured":"Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014, 20:808-14. 10.1016\/j.parkreldis.2014.05.011","journal-title":"Parkinsonism Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo M","year":"2021","unstructured":"L\u00e4hteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021, 81:1273-84. 10.1007\/s40265-021-01556-4","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q700","article-title":"Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia","volume":"46","author":"Wisniewski CS","year":"2012","unstructured":"Wisniewski CS, Robert S. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia. Ann Pharmacother. 2012, 46:1097-104. 10.1345\/aph.1Q700","journal-title":"Ann Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1006356","article-title":"Initiation of aripiprazole once-monthly in patients with schizophrenia","volume":"31","author":"Raoufinia A","year":"2015","unstructured":"Raoufinia A, Baker RA, Eramo A, Nylander AG, Landsberg W, Kostic D, Larsen F. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015, 31:583-92. 10.1185\/03007995.2015.1006356","journal-title":"Curr Med Res Opin"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal MM","year":"2003","unstructured":"Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan W, Feldman J. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003, 15:33-48. 10.3109\/10401230309085668","journal-title":"Ann Clin Psychiatry"},{"key":"ref24","article-title":"Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes","volume":"68 Suppl 6","author":"Lambert TJ","year":"2007","unstructured":"Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007, 68 Suppl 6:10-3.","journal-title":"J Clin Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.20471\/dec.2023.59.02.06","article-title":"Prevalence and correlates of extrapyramidal side effects among patients with schizophrenia spectrum disorders on typical and atypical antipsychotics","volume":"59","author":"Baba Shettima F","year":"2023","unstructured":"Baba Shettima F, Lateef Sheikh T, Abba Wakil M, Abdulaziz M, Bukar Rabebbe I, Abdulmalik J. Prevalence and correlates of extrapyramidal side effects among patients with schizophrenia spectrum disorders on typical and atypical antipsychotics. Arch Psychiatry Res. 2023, 59:225-40. 10.20471\/dec.2023.59.02.06","journal-title":"Arch Psychiatry Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404415-previously-incarcerated-veteran-a-case-of-drug-induced-parkinsonism","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T15:42:27Z","timestamp":1764949347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404415-previously-incarcerated-veteran-a-case-of-drug-induced-parkinsonism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.98525","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}